With rise of GLP-1 drugs, Peninsula biopharma targets another approach to diabetes and obesity

The founder and CEO of the startup worked on groundbreaking hepatitis C drugs as well as less-successful "fatty liver" drugs at Gilead Sciences.

Previous Wells Fargo employees at Albuquerque branch launch unionization campaign
Next Thomas Porter keeps building skills as he turns creative outlets into successful Phoenix businesses